CORONA Main Coronavirus thread

Zoner

Veteran Member

Upshot on dealing with the GVB endgame that Is likely this fall/winter.

If unvaxxed then you can wait until it’s clear that rate of death in vaxxed starts spiking, especially in local community. This means hospitals will start getting overwhelmed. That’s when the superspreader issue goes wide and threatens unvaxxed.

If vaxxed get ivermectin now twice weekly or even daily and ramp up daily dosing if others in community start dying.

At same time clean up lifestyle and optimize nutrient/supplement intake, make sure D is optimal by checking that PTH is suppressed (usually in low 20s at ideal D levels). Have high dose C on hand. There’s a lot more to this…

Anyway Ivermectin is so safe it’s better to err on side of taking than not.
 

psychgirl

Has No Life - Lives on TB

Upshot on dealing with the GVB endgame that Is likely this fall/winter.

If unvaxxed then you can wait until it’s clear that rate of death in vaxxed starts spiking, especially in local community. This means hospitals will start getting overwhelmed. That’s when the superspreader issue goes wide and threatens unvaxxed.

If vaxxed get ivermectin now twice weekly or even daily and ramp up daily dosing if others in community start dying.

At same time clean up lifestyle and optimize nutrient/supplement intake, make sure D is optimal by checking that PTH is suppressed (usually in low 20s at ideal D levels). Have high dose C on hand. There’s a lot more to this…

Anyway Ivermectin is so safe it’s better to err on side of taking than not.
Dr Haider is who DH and I went through initially (when DH was so sick with Covid pneumonia) to get our ivm!!

I still get his emails, but didn’t see or read that ^^^ yet.

Thanks for posting!
:)
 

Heliobas Disciple

TB Fanatic
(fair use applies)


Nearly 2 million excess deaths followed China's sudden end of COVID curbs - study
Bernard Orr
Thu, August 24, 2023, 10:50 PM ED

BEIJING (Reuters) - China's abrupt move to dismantle its strict COVID-19 regime, which unleashed the virus onto its 1.4 billion residents, could have led to nearly 2 million excess deaths in the following two months, a new U.S. study shows.

The study by the federally funded Fred Hutchinson Cancer Center in Seattle was taken from a sample of mortality data published by some universities in China and internet searches.

It found an estimated 1.87 million excess deaths from all causes occurred among people over 30 years of age between December 2022 and January 2023, and were observed in all provinces in mainland China except Tibet.

China's decision last December to end the three-year zero-COVID policy, which included mass-testing and stringent and persistent quarantine lockdowns, led to a massive surge in hospitalisations and deaths that health experts say were largely unreported by the government.

The study, published on Thursday in JAMA Network Open, said the number of excess deaths far exceeded official Chinese government estimates in January that 60,000 people with COVID-19 had died in hospital since the zero-COVID policy was abandoned a month earlier.

In the study, researchers performed statistical analysis using information from published obituaries and data from searches on Baidu, a popular Chinese internet search engine.

"Our study of excess deaths related to the lifting of the zero-COVID policy in China sets an empirically derived benchmark estimate. These findings are important for understanding how the sudden propagation of COVID-19 across a population may impact population mortality," researchers wrote.

China's National Health Commission did not immediately respond to a request for comment on the report.

Global health experts repeatedly called on China to reveal more data as reports of rising hospitalisations and deaths started to surface, and especially as the threat of new variants became a concern.

China stopped reporting official daily death results at the end of 2022. The World Health Organization says there have been 121,628 COVID deaths in China, out of a total global toll of almost 7 million.

In a rare move, one Chinese province briefly published data on its website in July showing cremations jumped 70% in the first quarter of this year that was later taken down.

In February, China's top leaders declared a "decisive victory" over COVID.

But the virus is still making its rounds in the country and on Thursday, Beijing health officials said COVID is still the number one infectious disease in the capital, according to Chinese state media.

Officials cited a new Omicron variant, called EG.5 or "Eris" nicknamed after the Greek Goddess of strife and discord, as the current dominant strain across China.

"The National Bureau of Disease Control and Prevention said the proportion of the new variant EG.5 increased from 0.6% in April to 71.6% in August, becoming the dominant strain in most provinces in China," the Global Times reported.
 

Heliobas Disciple

TB Fanatic
(fair use applies)


Highly mutated COVID variant found in new countries but pandemic in 'a different phase’

Jennifer Rigby and Julie Steenhuysen
Thu, August 24, 2023, 2:25 PM EDT

LONDON/CHICAGO (Reuters) - A highly mutated COVID variant called BA.2.86 has now been detected in Switzerland and South Africa in addition to Israel, Denmark, the U.S. and the U.K., according to a leading World Health Organization official.

The Omicron offshoot carries more than 35 mutations in key portions of the virus compared with XBB.1.5, the dominant variant through most of 2023 - a number roughly on par with the Omicron variant that caused record infections compared to its predecessor.

It was first spotted in Denmark on July 24 after the virus infecting a patient at risk of becoming severely ill was sequenced. It has since been detected in other symptomatic patients, in routine airport screening, and in wastewater samples in a handful of countries.

A dozen scientists around the world said while it was important to monitor BA.2.86, it was unlikely to cause a devastating wave of severe disease and death given immune defenses built up worldwide from vaccination and prior infection.

"It's still low numbers," Maria Van Kerkhove, COVID-19 technical lead at the WHO, said in her first interview regarding BA.2.86.

That the known cases are not linked suggests it is already circulating more widely, particularly given reduced surveillance worldwide, she said.

Scientists are testing how well updated COVID-19 vaccines will work against BA.2.86. Kerkhove noted that vaccines have been better at preventing severe illness and death than re-infection.

“We are in a very different phase (of the pandemic) than if this popped up in the first year,” said Marion Koopmans, a Dutch virologist who advises the WHO.

Dr. Nirav Shah, principal deputy director of the U.S. Centers for Disease Control and Prevention, said the agency and others spotted the new variant last week, held meetings with scientists throughout the weekend, and issued a risk assessment on Wednesday. There have been nine such cases detected as of Aug. 23 and the variant was also found in wastewater in Switzerland.

It appears that current tests and medications remain effective against BA.2.86, although the variant may be more capable of causing infection in vaccinated people and those who have had COVID previously, the assessment said. There is no evidence yet that it is causing more severe illness.

Still, the potential risk must be taken seriously, experts said, and surveillance must continue, if not at levels undertaken at the pandemic's peak.

"Governments cannot drop the ball," Van Kerkhove said, adding that the coronavirus continues to circulate, evolve, infect and kill people.

TESTING DOWN 90%

Another COVID subvariant called EG.5 already has some people on high alert in the U.S.

Pharmacy chains CVS, Walgreens and Rite Aid told Reuters on-site molecular tests and sales of at-home tests increased in recent weeks.

How much surveillance is needed to track the virus remains an open question, health experts said, and the countries that have detected the new variant all have strong genomic sequencing capacity. As of December 2022, 84% of countries could sequence Sars-CoV-2 in-country, according to WHO figures.

But data submitted to the international database, GISAID, has fallen dramatically. In the first week of Omicron, more than 200,000 coronavirus sequences were submitted. Last week, it was around 20,000.

“When we do sequencing now, it's like (finding) a needle in a haystack," said Tyra Grove Krause, a Danish epidemiologist at the Statens Serum Insitut which identified three BA.2.86 cases.

The WHO said COVID testing has declined by 90% worldwide from the peak. Testing has also plummeted in the U.S., and sequencing is down by around 90%, said Dr. Ashish Jha, who served as White House COVID-19 Response Coordinator until June 2023.

Data from hospital admissions, emergency room visits, deaths, wastewater sampling and sequencing, including at airports, has helped fill in the global picture, he said.

Jha and others, including the European public health agency and COVAX, the global program for getting vaccines to the world's poorest, said COVID surveillance and defenses could be reactivated in the event of a major infection wave.

"It would take resources; it would take will; it would take people deciding this is important to do," Jha said. "But ... we've largely figured out how."
 

Heliobas Disciple

TB Fanatic
(fair use applies)


COVID hospitalizations jump 22% this week — and CDC predicts further increases
Alexander Tin - CBS News
Updated Thu, August 24, 2023, 12:27 PM EDT

The Centers for Disease Control and Prevention is now forecasting an acceleration in new COVID-19 hospitalizations over the coming month, the agency said this week, replacing a previous projection that admissions would "remain stable or have an uncertain trend."

It comes as health officials are racing to study a new highly mutated COVID variant called BA.2.86, nicknamed "Pirola" on social media, that has begun to emerge around the world.

While officials say it is too early to know whether the strain will drive a further surge in COVID hospitalizations, the variant's broad number of mutations has prompted worldwide scrutiny.

Existing COVID-19 tests and medications "appear to be effective with this variant," the CDC said in a risk assessment published Wednesday, and updated vaccines scheduled to be rolled out next month are expected to "be effective at reducing severe disease and hospitalization" from BA.2.86.

But the strain's large number of mutations could also pose new challenges for immunity from prior infections and vaccinations, the agency warns. Further research with the BA.2.86 strain will be needed to better understand BA.2.86's potential impact.

How are COVID hospitalizations trending?

Trends in cases have been difficult to monitor meaningfully after the end of the public health emergency. Officials have leaned on figures still being reported from hospitals, like new admissions and emergency room visits, to track upticks in the virus.

Before BA.2.86's emergence, new admissions of patients with COVID-19 had already been climbing. Experts think this uptick in hospitalizations was mostly from infections caused by other less-mutated variants, similar to waves seen during previous summers.

Weekly new hospitalizations jumped 21.6% this past week, the CDC said, marking a fifth straight week of increasing admissions.

No unusual uptick in hospital trends so far has been spotted in places that reported early cases of BA.2.86 compared to neighboring regions, the CDC said, though officials will be closely monitoring rates in the weeks to come.

"It is also important to note that the current increase in hospitalizations in the United States is not likely driven by the BA.2.86 variant. This assessment may change as additional data become available," the agency said of BA.2.86.

Where has BA.2.86 been spotted?

According to records from GISAID, a global virus database, infections of BA.2.86 have been confirmed in at least five countries: South Africa, Denmark, the United Kingdom, Israel and the United States.

In the U.S., at least three states – Michigan, Virginia and Ohio – have reported the variant.

The first reported case had been sequenced by a lab at the University of Michigan, in an older adult who was not hospitalized.

A case was also later reported by CDC's airport testing program at Dulles International Airport in Virginia, from a sample of an asymptomatic woman who had traveled to Japan. That sample is now being scrutinized by CDC scientists.

"The identification of BA.2.86 was confirmed by genomic sequencing. The sample is currently at CDC laboratories for further characterization," Brookie Crawford, a spokesperson for Virginia's health department, told CBS News.

A sample from sewers in Ohio is also now being investigated after a preliminary detection of the variant in that state's wastewater.

"ODH is working with the CDC on further evaluation of the sample. As this preliminary detection has not been confirmed, ODH at this time cannot provide any further information," Ken Gordon, a spokesperson for the Ohio Department of Health, told CBS News in a statement.

Should you get another booster and mask up?

While far from previous peaks seen of the virus, the worsening COVID trends translates to nearly 10 million Americans now living in areas the CDC deems to be at "medium" COVID-19 levels.

Florida's Palm Beach and Hillsborough counties are among the most populous communities at this tier, where the agency urges some additional precautions for some people to avoid the virus.

Those recommendations include wearing a high quality mask when indoors in public, for people who are at high risk of severe disease.

For the general public, the agency says Americans should consider self-testing and masking for contact with others who are at high risk.

They also continue to urge people to get the updated COVID shots, after they are expected to be recommended next month, and stay home if you are sick.

"At this time, we don't know how well this variant spreads, but we know that it spreads in the same way as other variants," the CDC says.
 

Heliobas Disciple

TB Fanatic
(fair use applies)


Severe COVID-19 survivors may show increased vascular risk associated with stress
by D'Or Institute for Research and Education
August 24, 2023


severe-covid-19-surviv.jpg

Vascular responses to mental stress in COVID-19 survivors. Forearm blood flow (FBF) during mental stress (MS) in control subjects and in severe COVID-19 survivors (A); delta FBF (B); forearm vascular conductance (FVC) (C); and delta FVC (D). BL, baseline; Rec, recovery. *P < 0.05 vs. BL; †P < 0.05 vs. control subjects. Credit: American Journal of Physiology-Regulatory, Integrative and Comparative Physiology (2023). DOI: 10.1152/ajpregu.00111.2023


Recently published in the journal American Journal of Physiology, a Brazilian study demonstrated for the first time that survivors of severe COVID-19 infections may have elevated muscle sympathetic nerve activity (MSNA) in response to mental stress.

The study was carried out by the D'Or Institute for Research and Education (IDOR), in partnership with the University of São Paulo (USP), the Federal University of São Paulo (Unifesp), and the University of Colorado Boulder. Its results are a warning for the so-called long COVID, chronic sequelae left by the disease that could increase the risk of cardiovascular diseases.

Although many patients recover completely from the disease, previous studies led by the same scientists noted cardiovascular sequelae in patients that survived severe COVID-19 infections.

The research concluded that this population presents increased risk factors for cardiovascular complications, such as excessive muscle sympathetic nerve activity (MSNA), which has the acceleration of the heartbeat as one of its duties, in addition to other problems, such as greater stiffness in the main artery of the human body and dysfunctions in peripheral blood vessels, which are responsible for regulating blood flow and blood pressure.

These results encouraged the team to deepen the research and understand the reaction of these patients to exposure to stress and physical activity, matters that also interfere with cardiovascular health.

The current publication analyzed 15 patients who had survived severe COVID-19 hospitalizations, in ICUs or wards, with a confirmed RT-PCR diagnosis and oxygenation levels equivalent to or lower than 93%. As a control group, 15 volunteers who had never had the disease, had no comorbidities, and were of similar age and body mass index (BMI) were chosen. The research was developed between September 2020 and October 2021, at a time when the dominant variants were beta and gamma, and none of the participants had been vaccinated.

To measure the effects of stress, patients and the control group were exposed to a 3-minute activity in which slides were projected in front of them and the image changed every 2 seconds, accompanied by conflicting sounds that were delivered through headphones. At the end of the analysis, it was concluded that all participants noticed a similar increase in the level of stress, but that in patients who had COVID-19, some physiological reactions were discrepant.

The authors mention that the ANSM of these survivors is already around 65% higher than that of those who did not have the disease. However, during the stress exposure activity, the increase in ANSM in patients who had COVID-19 was 128% greater than in the control group.

The authors also measured vascular responses to this stress induction and analyzed blood flow, vascular function, and mean arterial pressure across each participant's forearm. The analysis showed that the first two aspects were attenuated in COVID-19 patients, being more than 100% lower when compared to the control group, while mean arterial pressure was similar in all individuals.

The other test carried out by the study sought to analyze the same markers during muscle stimuli in the participants, an activity that was performed through the voluntary contraction of the hands, in a manual prehension movement (act of squeezing). In this case, the observed results were different: ANSM, blood flow, and vascular function were similar between the groups, suggesting that the blood flow control mechanisms in the vascular system remain preserved in COVID-19 survivors.

The only discrepancy between the groups in the handgrip test was related to mean arterial pressure, which was reduced in patients with COVID-19, an aspect that the authors believe to be related to the previously observed blood vessel dysfunctions in the group.

However, the scientists point out that, even if the neurovascular response has not shown relevant changes between the groups in strength exercise, other evaluations with aerobic exercises would add interesting observations related to physical activity and patients who have overcome COVID-19.

This study was the first to prove that some COVID-19 survivors have an exaggerated ANSM in response to mental stress, as well as an attenuated vasodilation reaction compared to individuals who did not have the disease. This finding demonstrates a warning regarding the increased risk for cardiovascular diseases, and that patients who survived severe COVID-19 should remain attentive to routine exams and health care, even after the apparent overcoming of the infection.

More information: Diego Faria et al, Neurovascular and hemodynamic responses to mental stress and exercise in severe COVID-19 survivors, American Journal of Physiology-Regulatory, Integrative and Comparative Physiology (2023). DOI: 10.1152/ajpregu.00111.2023
 

Heliobas Disciple

TB Fanatic
(fair use applies)


What's driving turbo cancers and autoimmune flare-ups?
Vaccinologist Geert Vanden Bossche explains the possible mechanism for the widely reported spikes in aggressive cancers and autoimmune flares.

By Rob Verkerk PhD, executive & scientific director, ANH-Intl and ANH-USA
23 August 2023

230824-geert-article-feat.jpg


IMPORTANT NOTES:

1. Multiple download links to Geert Vanden Bossche’s latest treatise can be found throughout this article. [MY COMMENT: I didn't copy them all over, just the first time it was posted, link leads to a pdf file]
2. In the following article, C-XX refers to the respiratory disease associated with a novel virus that became subject to a pandemic declared by the World Health Organization in March 2020. This edit was made given the immediate censorship of the following article on legacy platforms when the well-known disease name was included.

Pointed or pointless?​

The public is understandably confused. On the one hand, major scientific journals, news outlets and authorities have used, and continue to use, superlatives to describe C-XX genetic vaccines. The journal Science called the results of a Moderna trial “absolutely remarkable”, the Washington Post referred to them as “an extraordinary success story”, BuzzFeed claimed the vaccines “work way better than we had ever expected”, while the US Centers for Disease Control and Prevention (CDC), the UK National Health Service (NHS) and other authorities continue to cite the mantra used for all approved vaccines, referring them as “safe and effective” (here and here, respectively).

>>> Download Geert Vanden Bossche’s latest report, “Immunological correlates of vaccine breakthrough infections caused by SARS-CoV-2 variants in highly C-XX vaccinated populations”

Conflicting information about an uncertain and unpredictable interaction​

Yet, on the other hand, the scientific literature is increasingly awash with articles that suggest something quite different.

The CDC is still telling US citizens to “stay up to date” with their shots, yet a preprint study released in June shows that Cleveland Clinic staff who weren’t “up-to-date” with their C-XX shots fared better against C-XX than those who were.

As early as 2021, as indicated in an article in Nature Medicine, “viral variants began to stack up” only after the vaccines were rolled out. An article published in Frontiers in Immunology in early 2022 details the multiple immune escape strategies used by the virus both following infection and vaccination.

Then there’s people’s individual experiences, with many who have been heavily vaccinated not experiencing good outcomes, either in relation to C-XX disease, a concern noted in the recently published Cleveland Clinic study – but also in relation to other diseases or conditions, cancer and autoimmune diseases included.

Emergency over – or not?​

For most people, the C-XX crisis is over. That’s largely a consequence of the World Health Organization’s declaration in May this year that the “public health emergency” was no longer.

There are at least two reasons it is likely wrong to think that the C-XX drama is behind us.

The first is that the virus is still very much out there, circulating to its non-existent heart’s content. While it remains at large, it is susceptible to natural selection of immune escape variants. Secondly, it seems authorities have no inclination to sideline C-XX shots. By contrast, they want to keep using them, and no doubt will use any obvious waves of C-XX disease as we progress towards the northern winter to justify more vaccination.

There is no shortage of acclaimed ‘experts’ who can confirm for you that SARS-CoV-2 hasn’t transitioned to an endemic, seasonal pattern, as naturally-occurring respiratory viruses typically do after the pandemic phase. It’s still very much around as you may have noticed in you own circles — it’s just not being surveilled with the same intensity via C-XX testing stations dotted around each and almost every industrialised country. Ditching the nationwide testing programmes wasn’t just seen as a waste of resources, it might also have been recognised that its continuation would dent people’s faith in the genetic vaccines, a reputation the establishment seems very keen to protect.

An article just published in STAT included feedback from numerous acknowledged experts in the field, ones aligned with the mainstream scientific establishment, including Michael Osterholm, director of the University of Minnesota’s Center for Infectious Disease Research and Policy. Most of the experts interviewed confirm that the virus has yet to achieve true endemicity and seasonal patterns.

This equates with the lack of understanding of how population-level immunity shapes the evolutionary dynamics of the virus, a phenomenon that is greatly complicated by the genetic vaccination programme. In fact, it is this poor insight that remains one of the most defining characteristics of a virus put under immune selection pressure after its release on human populations over three years ago, making a mockery of much of the predictive modelling that has been undertaken to-date.

Conflicting information doesn’t just create confusion. It creates cognitive dissonance. That’s an uncomfortable and unsettling feeling – and it drives people to find, and latch onto, what feels to them like a coherent, trusted view. This causes division. Some still have trust in the authorities and the scientific establishment that remain steadfastly on the ‘vaccines-are-our-best-fix’ podium. Others of us cannot support this view, seeing it as incoherent, both scientifically and experientially.

Many of us have lost trust in the scientific establishment, full stop. See here and here for our reasons why. Any trust that we might have had prior to the C-XX crisis has since evaporated, largely because of the way the crisis, and information relating to it, was handled. That includes the mass censorship of dissenting scientific views.

Given the social nature of human beings, and our desire to align with those we trust, if we are repelled by one group we distrust – such as the scientific establishment responsible for our ‘C-XX worldview’ – we find ourselves being attracted to others with whom we see reason to trust.

GVB – dedicated to better understanding the uncertainty

It is in this vein that I get to the main purpose of the present piece. It is to introduce you to a new article by a person who has been something of an icon for many of us who have been attempting to grapple with the complexity of our immune systems’ dance with the ever-changing SARS-CoV-2 virus. Changes that have been undoubtedly amplified greatly by the global C-XX vaccine programme. The person to whom I refer is of course immunologist and vaccinologist, Geert Vanden Bossche DVM, PhD, a person I admire greatly both for his scientific rigour and his resolve, but also for his bravery in the face of the monolith we might refer to as the scientific-medical-industrial complex. I am also humbled to regard Geert as both an ally and a friend.

Before offering you a précis of Geert’s latest thoughts based on extensive evidence, all compiled in a brand new report, I also want to highlight that Geert has dedicated this report, that we have designed into a standalone publication, to John Heathco, a computer engineer and self-confessed “health & wellness junkie”, who died suddenly and tragically in June, along with his girlfriend.

>>> Watch Rob Verkerk Speaking Naturally with GVB about immune escape [1 hr 11 min 43 sec]

On June 13, John and his girlfriend, Abby Lutz, died tragically overnight while in a 5-star hotel, on holiday in Mexico, following “intoxication by an undetermined substance”. It turns out the substance may have been carbon monoxide from a gas leak. In John, we lost a dear friend and ally in the freedom and truth movement, someone who’s passion to understand the complexities of our interaction with this virus had drawn him to Geert, and Geert’s work. A very sad loss, a loss of someone who had increasingly become a key support pillar for Geert. So when Geert reached out to me after returning from California for a celebration of John and Abby's lives, asking if we might publish the article through ANH, we were only too happy to help.

So we too, make this dedication to John and to Abby. Fly free, together, without limits.

In a nutshell​

In his article, Geert Vanden Bossche sends a stark warning to those contemplating more C-XX shots later this year, as we proceed towards the northern hemisphere winter. He explains in great detail how and why highly C-XX vaccinated populations will:
  • serve to drive ever more infectious and potentially dangerous, immune escape, Omicron-derived variants
  • be at greater risk of severe C-XX than less vaccinated or unvaccinated populations, and
  • how the risk of other conditions among highly vaccinated populations, including aggressive, early-onset, ‘turbo’ cancers and autoimmune flare-ups, will likely increase significantly compared with those who choose to avoid further C-XX vaccination.
The evidence base pointing in this direction is becoming ever stronger (with many references being made to other literature in Geert’s report). What is more a matter of debate is the mechanisms driving specific interactions, as opposed to the end result. The objective and deterministic world that has delivered so much technology seems incapable of accepting something unless a mechanism is given. Observation, measurement or experience on their own are not enough. We all crave knowing why and how something happens, and we’ll so often deny it’s existence if we’re not given an explanation for how it works.

Knowing what we already know, it is a travesty that such large swathes of the public still have confidence in C-XX vaccines, the vehemence of this position in the public’s mind reflecting the power of the machine driving the agenda.

In the simplest terms I can muster, this is what Geert is suggesting is going on, including the elements that are a well-known part of the immune cascade that occurs following infection or vaccination.

What Geert argues is that if you keep vaccinating large cohorts of people while the mutation-prone virus continues to circulate (i.e. during a pandemic), the cascade of events moves in a different direction to that which occurs with natural infection from a virus that enters via the respiratory system.

C-XX vaccination induces a range of immune responses, the target as far as vaccine makers are concerned being the neutralising antibodies made in the B cells of the adaptive immune system that take some weeks to mount an optimal response. For vaccinees, this immune response is triggered by the slightly modified version of the virus’ spike protein that is expressed in cells of the body, but of course, most also encounter the wild virus that infects the upper respiratory tract.

What has been revealed without any doubt over the last couple of years is that these all-important neutralising antibodies don’t work effectively within the context of an immune escape pandemic. That’s been especially the case since the Omicron variant evolved, itself being a response to the extreme immune selection pressure from mass vaccination.

The hope had been that when a vaccinated person becomes infected with the real virus, these neutralising antibodies would bind primarily to the receptor-binding domain (RBD) displayed at the end of the coronaviruses spikes around the surface of the virus. These in turn block the ability of the virus to dock with ACE2 receptors even when the RBDs are in their primed, ‘open’ position, and it is the ACE2 receptors on the epithelial cells of our bodies; these receptors provide the doorways that allow these viruses into our bodies, assuming they haven’t been blocked by the neutralising antibodies.

211111_sars-cov2_infographic.png


But, in the case of large parts of the population are vaccinated while being exposed to the virus, these neutralising antibodies do the job imperfectly because their affinity and/or titers (or: concentration in the blood) are still too low when they encounter the virus. This is because, after infection, it takes a few weeks for these antibodies to proliferate and mature in germinal centers and to (get them to) perform at their best.

There’s also another kind of antibody produced by B cells, called non-neutralising antibodies. These are typically elicited in the presence of vaccinal Abs with strongly diminished neutralizing capacity; they are short-lived and do not mature into high-affinity antibodies. As their production is thought to be triggered by a repetitive antigenic pattern displayed on multimeric viral assemblies (so-called viral aggregates) they are called ‘polyreactive’ non-neutralising antibodies (PNNAbs). These antibodies bind to the virus but instead of neutralising the virus, they enhance its entry into susceptible epithelial cells, thereby causing PNNAb-dependent enhancement of viral infectiousness.

[CONTINUED NEXT POST]
 

Heliobas Disciple

TB Fanatic
[CONTINUED FROM ABOVE POST]

One of the features of the early Omicron-derived immune escape variants was that they drove repeated re-stimulation of PNNAbs in vaccinees (due to the strongly diminished neutralizing capacity of vaccine-induced Abs) and history was made when Omicron became the first SARS-CoV-2 variant to cause PNNAb-dependent breakthrough infections in heavily vaccinated populations. This contrasts with the immune escape variants that circulated prior to Omicron. Resemblance of their spike protein to the one used in the vaccines was still good enough to drive ‘original antigenic sin’, that we explained in an article we published on our website in November 2021 (see image from this article above) on which Geert and I collaborated. These variants, therefore, recalled previously vaccine-induced antibodies. However, as the latter became increasingly less effective in neutralizing newly emerging variants, the ‘antigenic sin’ effect only contributed to furthering viral immune escape.

But, sadly, it doesn’t end there. Complications arise because there are multiple classes of antibodies. Many will have heard that the neutralising antibodies belong to a group of proteins called immunoglobulins of which there are multiple classes or isotypes, notably A, D, E, G and M, giving the names IgA, IgD, IgE, IgG, IgM, and so on. These in turn have subclasses, and one that is central to Geert’s concern is one of SARS-CoV-2 spike-specific IgG subclasses called IgG4. Making matters more complicated, the immune system, being as versatile as it is, also has the capacity to engage in immunoglobulin class switching, sometimes also known as isotype switching.

While there’s been a lot of work showing IgG and IgA are elevated for a number of weeks post infection or vaccination, there is now a clear sense that one sub-class of IgG that is normally present at the lowest levels, IgG4, is becoming more prevalent, especially as a result of delayed affinity maturation into a class switched IgG4 isotype in those who are heavily vaccinated without prior infection. This therefore applies to the majority of vulnerable people in heavily vaccinated countries.

This is where things become really interesting – and even more concerning.

Two clear mechanisms appear to operate in parallel.

Firstly, the PNNAb-driven breakthrough infections cause a phenomenon known as steric immune refocusing (SIR) which causes insufficiently neutralising anti-spike antibodies to bind weakly (or: with low affinity) to the ‘immune dominant’ domains of the spike of SARS-CoV-2 (primarily situated within the RBD). As their binding masks the 'immunodominant’ parts of the spike antigen, other spike-associated domains that are subdominant or immune recessive are no longer outcompeted for eliciting their own, broadly neutralizing antibodies. However, as the latter are directed to weakly immunogenic domains (i.e., immune subdominant or immune recessive), titers of these antibodies are low and rapidly decrease, thereby fostering enhanced immune escape.

Secondly, there is the all-important elevation of IgG4 titers. The IgG4 class switch appears to be a last-ditch mechanism by the body to try to deal with the lack of effectiveness of both types of neutralising antibodies, and innate immunity which should have delivered the first salvo of attack but failed to do so because Omicron and its descendants cause vaccine breakthrough infections which expedite production of viral progeny and therefore fail to trigger cell-based innate immune cells (e.g. Natural Killer cells). Ongoing large-scale vaccine breakthrough infections due to more infectious Omicron descendants then place continuous immune selection pressure on circulating viruses that continue to try and work around the body’s defences. The lack of sterilising immunity coupled with the immune selection pressure towards newly emerging immune escape variants means that a cycle is set up in highly vaccinated populations that have no mechanism to dampen out circulating infection. More and new breakthrough variants are created, and the cycle goes on - and on, with no development of true herd immunity.

This loop is something that wouldn’t have occurred if populations had not been massively vaccinated during this pandemic. mRNA vaccines are only expediting immune escape as they promote immune refocusing (refer to Geert’s book, The Inescapable Immune Escape Pandemic, published February 2023). That’s because the innate immune system would have been triggered, therefore trained and have come to the rescue, delivering natural killer cells and other biochemical and cellular weaponry that would have nailed infection much earlier, as it did in children (who have highly effective innate immune systems) during the early days, weeks and months of the pandemic, before the vaccines were introduced.

The process of steric immune refocusing (SIR) combined with delayed IgG class-switching to IgG4 that may in the short-term lessen symptomatic infection appears to also side-line the innate immune system. Not only that, it severely compromises antigen presentation and thereby prevents sustained stimulation of PNNAbs, which likely protect vaccinees from severe disease. While shifting protective adaptive immune responses from long-lived to short-lived, SIR and elevated IgG4 Ab titers are also driving large-scale immune escape which may ultimately turn new, more infectious, immune escape variants into lineages of the virus that are highly virulent in fully vaccinated individuals.

IgG4 has widely been regarded as benign or even beneficial in health and disease, the latter owing to its well described and often helpful response when encountering allergens or parasites. But there is a growing body of research showing that elevated IgG4 titers in the bloodstream, something that tends to be more common in chronic, long-term infections – and now with C-XX mass vaccination – may be detrimental and can be particularly problematic as it compromises antitumour responses and is associated with flare-up of autoimmune diseases. Some of the latest perspectives on this Jeckyll & Hyde nature of IgG4 is laid out in a recent review in Nature Reviews Immunology.

This is exactly the emerging picture we are dealing with; highly aggressive, ‘turbo’ cancers and autoimmune flare-ups among the heavily vaccinated are being reported by exactly the same clutch of doctors and practitioners who first reported success with early treatments against C-XX, including ivermectin. That practitioner group was then silenced and marginalised. The truth, it seemed, was inconvenient.

Are we seeing a repeat of recent history? Are we inching ever closer to a time when authorities will be forcing the masses to line up once again for more shots as symptomatic C-XX disease rises (an uptick is already being noted in some official records), in the blind hope that a failed technology that’s generated the problem might now resolve it?

When will we learn? Or, should we take better note of a quote that is often misattributed to Einstein, Insanity is doing the same thing over and over again and expecting different results?"

>>> Interested in learning more from Dr Vanden Bossche? Join his upcoming course, The immune biology of natural and immune escape pandemics/epidemics, starting 27th September 2023 for 12 weeks at 7:00 pm EST. Enroll here.
 

Heliobas Disciple

TB Fanatic
(fair use applies)


Biden to request funds for another COVID vaccine amid rising cases
Tara Suter - The Hill
Fri, August 25, 2023, 11:15 PM EDT

President Joe Biden on Friday said he plans to ask for more funding from Congress for the development of a new coronavirus vaccine.

“I signed off this morning on a proposal we have to present to the Congress a request for additional funding for a new vaccine that is necessary, that works,” Biden, who is vacationing in the Lake Tahoe area, told reporters.

“It will likely be recommended that everybody get it no matter whether they’ve gotten it before or not,” he added.

The announcement comes as a recent rise in COVID-19 cases in some regions has resulted in the return of mask mandates by some entities in the U.S. Hospitalizations due to COVID-19 have also risen in the past few weeks as well, according to data.

New vaccines containing the version of the omicron strain XBB.1.5 are already being developed by Pfizer, Novavax and Moderna. However, the virus’s continuing mutation will likely necessitate updated vaccines.

The Biden administration’s supplemental funding request for Congress for the start of the new fiscal year did not include COVID-19 vaccinations. Instead, the White House asked for roughly $40 billion to fund short-term key priorities such as more aide for Ukraine, federal disaster funds, climate change and border priorities.

Last fall, Biden asked for over $9 billion from Congress to combat the virus, but the request was denied.
 

Heliobas Disciple

TB Fanatic
(fair use applies)


U.S. Medical News: U.S. CDC Forecasts That COVID-19 Hospitalizations In America Can Rise Up To 7,500 Admissions Per Day By 18th Of September 2023
Thailand Medical News
Aug 25, 2023

The United States Centers for Disease Control and Prevention (CDC) Agency is predicting a gloomy forecast just before the start of fall with daily hospitalizations to reach between 1,100 up to 7,500 admissions per day by the 18th of September 2023.


Presently existing SARS-CoV-2 sub-lineages like the XBB 1.16, FL.1.5.1, XBB.1.16.6, EG.5.1.1, EG.5.1 ad many others are driving the start of the surge in the United States.

View: https://twitter.com/RajlabN/status/1694932224943009930/photo/1


However, the emergence of various more transmissible and immune evasive spawns of the EG.5.1 variants such as HK.1 aka EG.5.1.1.1, HK.2 aka 5.1.1.2, HK.3 aka 5.1.1.3 and HK.3.1 aka EG.5.1.1.3.1 along with other newer sub-lineages that are bearing better viral fitness along with enhanced transmissibility and immune evasiveness are likely to supersede all the current predominant sub-lineages in current weeks and cause an exponential rise in daily COVID-19 infections.





It is already being anticipated that this coming Autumn and Winter of 2023 is expected in United States and also in many other countries as the SARS-CoV-2 virus is rapidly evolving to evade all kinds of immunity and even antivirals etc. Also, the chances of more pathogenic variants and disease severity causing variants likely to emerge are very high.

Also, the Autumn and Winter seasons are likely to also see the rise of other respiratory diseases as well including Flu infections, RSV infections, Adenovirus infections etc.

In the week leading up to August 12, there were a total of 12,613 hospital admissions of patients who tested positive for COVID-19 in the United States.


However, this number was just slightly over a third of the admissions observed during the same period last year, which amounted to approximately 40,000 admissions per week.

Regarding fatalities, the numbers have remained relatively stable. In the latest available data from the week ending on July 22, there were 479 reported deaths compared to 484 in the previous seven-day period.


Medical professionals working on the frontlines have remarked that the current wave of COVID-19 cases is resulting in milder illness among patients compared to earlier phases of the pandemic.

Nevertheless, concerns related to the emergence of new variants have prompted a resurgence in the usage of masks in everyday life.

Notably, two prominent hospitals, namely Kaiser Permanente in Santa Rosa, California, and Upstate Community Hospital in Syracuse, New York, collectively serving a substantial number of Americans, have reintroduced mandates for the wearing of masks by doctors, nurses, patients, and visitors.

The requirement for wearing masks has been introduced due to an increase in hospital personnel falling ill with COVID-19.

Dr Stephen Thomas, the Director of Global Health at Upstate, stated that while the figures are dynamic, there is a noticeable rise in COVID-related hospital admissions within our locality. He told U.S. Medical News reporters from TMN, "Although we are not yet at the levels observed during the peak of the pandemic, the number of patients presently exceeds that of a month ago. Fortunately, our ability to tend to all our patients remains comfortably within our capacity."

The U.S. CDC recommends that certain high-risk individuals, including older adults, individuals with specific medical conditions, and pregnant individuals, should wear masks. Additionally, it advises mask usage in regions where there are 20 or more COVID-19 hospitalizations per 100,000 people.


Dr Robert Wachter, who leads the medical department at the University of San Francisco, mentioned, "While hospitalizations haven't yet doubled, it's highly likely they will, given that there's typically a lag of a couple of weeks in the numbers. The risk of getting infected now is considerably higher than it was a month or two ago - probably twice as high. If you're aiming to take precautions, it's a good time to reintroduce the use of masks."

Mask mandates are being reintroduced gradually due to the rise in COVID-19 hospitalizations in many other places as well. The extent of this reintroduction remains uncertain due to the polarized nature of the measure. In recent weeks, several businesses and schools in the U.S. have reinstated mask mandates in response to the growing number of COVID-19 hospitalizations.

Reports suggest that Lionsgate, a movie studio, is also enforcing a mask requirement again at its Santa Monica headquarters.

In Georgia, a small liberal arts college has made it mandatory for students to wear masks for a period of two weeks as COVID-19 cases increase among the student body. Morris Brown College has additionally placed restrictions on campus events.

The college stated, "Over the next two weeks, there will be no parties or large student events on campus." The future implementation of mask mandates in various institutions remains uncertain due to the contentious views surrounding the measure. These developments coincide with a continuous fifth-week surge in COVID-19 hospitalizations, as indicated by data from the Centers for Disease Control and Prevention.

The tracking of daily COVID-19 infections in America is no longer being carried out by the U.S. CDC. However, researchers indicate that the rise in hospitalizations suggests a likely significant spread of the virus. Although there hasn't been a corresponding increase in deaths yet, which usually follows after hospitalizations rise.

In recent days, the U.S. CDC has released an evaluation of risk concerning a novel and highly mutated subvariant of the omicron variant, designated as BA.2.86.


The CDC's assessment suggests that this new subvariant probably isn't the main cause behind the current surge in COVID-19 hospitalizations. Nonetheless, it's too early to ascertain the transmissibility and severity of this new strain.

Nonetheless, experts are optimistic that the updated iteration of the COVID-19 vaccine, expected to be introduced next month, will remain effective against the BA.2.86 subvariant. The risk assessment from the CDC states, "Based on current evaluation, it is anticipated that this updated vaccine will effectively mitigate severe illness and the need for hospitalization."

Despite its possession of more than 30 mutations, the prevalence of this strain hasn't reached a level where it would be included in the CDC's list of monitored variants. Nevertheless, it has been identified in small numbers in multiple countries including the U.S., the U.K., Denmark, Israel, South Africa, Switzerland and Thailand.




The World Health Organization recently elevated its status to that of a "variant under monitoring."
 

northern watch

TB Fanatic

Researchers Create Aerosolized COVID Vaccine.

1693087591968.png

The National Pulse
August 26 2023

Yale University researchers have created a new airborne method of delivery for mRNA vaccines which they believe will radicalize the way people are vaccinated in the near future. Their findings are detailed in a report published in the journal Science Translational Medicine. “In the new report, there is no intramuscular injection,” said Professor Mark Saltzman.

“We just gave two doses, a prime and a boost, intranasally, and we got a highly protective immune response. But we also showed that, generally, you can deliver different kinds of mRNA. So it’s not just good for a vaccine, but potentially also good for gene replacement therapy in diseases like cystic fibrosis and gene editing. We used a vaccine example to show that it works, but it opens the door to doing all these other kinds of interventions.”

– Prof. Mark Saltzman, 2023.

The news comes at a time when COVID is back in the headlines, with unearthed documents revealing the Department of Defense has spent millions of dollars on new COVID equipment contracts that due to begin in September and October 2023.

The issue also raises questions aerosolized vaccines being deployed without people’s consent or awareness. Biotechnologists have argued for years in respectable academic publications that “compulsory moral bioenhancement should be covert”.

As reported by the National Pulse, mRNA vaccines have been used on pig herds in the US since at least 2018, with only farmers and vaccine manufacturers generally aware of it.

The Missouri state senate took up legislation to ensure clear labelling of products containing “gene therapy” technology this year, receiving ferocious attacks from “Big Agriculture” and its representatives in the chamber. The bill was defeated.

 

northern watch

TB Fanatic

Researchers Create Aerosolized COVID Vaccine.

View attachment 432118

The National Pulse
August 26 2023

Yale University researchers have created a new airborne method of delivery for mRNA vaccines which they believe will radicalize the way people are vaccinated in the near future. Their findings are detailed in a report published in the journal Science Translational Medicine. “In the new report, there is no intramuscular injection,” said Professor Mark Saltzman.

“We just gave two doses, a prime and a boost, intranasally, and we got a highly protective immune response. But we also showed that, generally, you can deliver different kinds of mRNA. So it’s not just good for a vaccine, but potentially also good for gene replacement therapy in diseases like cystic fibrosis and gene editing. We used a vaccine example to show that it works, but it opens the door to doing all these other kinds of interventions.”

– Prof. Mark Saltzman, 2023.

The news comes at a time when COVID is back in the headlines, with unearthed documents revealing the Department of Defense has spent millions of dollars on new COVID equipment contracts that due to begin in September and October 2023.

The issue also raises questions aerosolized vaccines being deployed without people’s consent or awareness. Biotechnologists have argued for years in respectable academic publications that “compulsory moral bioenhancement should be covert”.

As reported by the National Pulse, mRNA vaccines have been used on pig herds in the US since at least 2018, with only farmers and vaccine manufacturers generally aware of it.

The Missouri state senate took up legislation to ensure clear labelling of products containing “gene therapy” technology this year, receiving ferocious attacks from “Big Agriculture” and its representatives in the chamber. The bill was defeated.

This scares me the most
 

Countrymouse

Country exile in the city

Researchers Create Aerosolized COVID Vaccine.

View attachment 432118

The National Pulse
August 26 2023

Yale University researchers have created a new airborne method of delivery for mRNA vaccines which they believe will radicalize the way people are vaccinated in the near future. Their findings are detailed in a report published in the journal Science Translational Medicine. “In the new report, there is no intramuscular injection,” said Professor Mark Saltzman.

“We just gave two doses, a prime and a boost, intranasally, and we got a highly protective immune response. But we also showed that, generally, you can deliver different kinds of mRNA. So it’s not just good for a vaccine, but potentially also good for gene replacement therapy in diseases like cystic fibrosis and gene editing. We used a vaccine example to show that it works, but it opens the door to doing all these other kinds of interventions.”

– Prof. Mark Saltzman, 2023.

The news comes at a time when COVID is back in the headlines, with unearthed documents revealing the Department of Defense has spent millions of dollars on new COVID equipment contracts that due to begin in September and October 2023.

The issue also raises questions aerosolized vaccines being deployed without people’s consent or awareness. Biotechnologists have argued for years in respectable academic publications that “compulsory moral bioenhancement should be covert”.

As reported by the National Pulse, mRNA vaccines have been used on pig herds in the US since at least 2018, with only farmers and vaccine manufacturers generally aware of it.

The Missouri state senate took up legislation to ensure clear labelling of products containing “gene therapy” technology this year, receiving ferocious attacks from “Big Agriculture” and its representatives in the chamber. The bill was defeated.

I think THIS post should have its OWN thread---this is a MAJOR new development.

Wonder if the admins would allow -- even just temporarily???
 

Heliobas Disciple

TB Fanatic
(fair use applies)


Highly mutated COVID variant BA.2.86 ‘Pirola’ has been detected in the U.S. Why the CDC and WHO are monitoring it
Erin Prater - Fortune
Sat, August 26, 2023, 5:00 AM EDT

The World Health Organization and the U.S. Centers for Disease Control and Prevention are tracking a newly identified, highly mutated strain of COVID experts warn could be the next big leap in viral evolution—if the variant takes off.

The WHO last week announced that it had declared BA.2.86—formerly referred to as BA.X and dubbed “Pirola” by variant trackers, after an asteroid—a “variant under monitoring,” the lowest of three levels of alert. “High flying” variants EG.5, XBB.1.5, and XBB.1.16 have been designated as “variants of interest,” of greater concern. “Variant of concern” persists as the highest level of alert.

WHO has designated #COVID19 variant BA.2.86 as a ‘variant under monitoring’ today due to the large number of mutations it carries.
So far, only a few sequences of the variant have been reported from a handful of countries.
— World Health Organization (WHO) (@WHO) August 17, 2023

Later that day, the CDC announced that it, too, was tracking the variant, and that it had been detected in the U.S.—in Michigan, in addition to Israel and Denmark, where it had first been reported earlier in the week.

CDC is tracking a new lineage of the virus that causes COVID-19. This lineage is named BA.2.86, and has been detected in the United States, Denmark and Israel. CDC is gathering more information and will share more about this lineage as we learn it.
— CDC (@CDCgov) August 18, 2023

The next day, the U.K. Health Security Agency (HSA) said that the variant had been identified in England, and that it was "assessing the situation." The patient ill with BA.2.86 is elderly and hospitalized, Raj Rajnarayanan—assistant dean of research and associate professor at the New York Institute of Technology campus in Jonesboro, Ark., and a top COVID-variant tracker—told Fortune. They have no recent travel history, according to a risk assessment for the variant published Friday by the agency.
A case of the COVID-19 variant BA.2.86 has been identified in the UK & a number of other countries. Dr Meera Chand, Deputy Director, has said "We're aware that BA.2.86 has been detected in the UK. UKHSA is assessing the situation & will provide further information in due course."
— UK Health Security Agency (@UKHSA) August 18, 2023

Unlike most circulating variants, which have evolved from Omicron spawn XBB, BA.2.86 is thought to have evolved from a much earlier strain of Omicron—BA.2, which circulated in early 2022, or perhaps from the original Omicron, B.1.1.529, which spiked cases to record highs in late 2021 and early 2022.

And it appears to be vastly different from its predecessors. So far, most widely circulating Omicron variants feature a small handful of mutations that make them slightly different from the last—usually a bit more transmissible.

BA.2.86, on the other hand, features 30 or more mutations that separate it from other Omicron—mutations with the potential to make it considerably more immune-evasive, and able to more easily infect cells, according to Jesse Bloom, a computational biologist at Fred Hutch Cancer Center in Seattle, Wash., and top variant tracker.

That makes BA.2.86 as different from other Omicron strains as the first Omicron was from the original strain of COVID found in Wuhan in 2019, Bloom asserts in a widely cited presentation he posted online.

Because of this, “Pirola” has the potential to become the next variant the WHO awards a Greek letter to—likely Pi, hence the nickname.

“What sets this one apart from the many other Omicron subvariants is that it exhibits a large number of mutations … far more than we usually see,” Ryan Gregory, a biology professor at the University of Guelph in Ontario, told Fortune. He’s been assigning “street names” to high-flying variants since the WHO stopped assigning new Greek letters to them.

While only six (unrelated) cases—and counting—of the variant had been identified in four countries as of late Friday, sequencing worldwide is at an all-time low.

“It’s fairly likely it’s going undetected in some other countries,” Gregory said.

The fact that the cases are geographically dispersed, with no travel history, "suggests there is established international transmission" that may have occurred only recently, the U.K. HSA said in its risk assessment. There may be a degree of community transmission in the U.K., it added.

Regarding BA.2.86, when @SolidEvidence uses the word "avalanche," it's not a good sign.
And here's the 30+ ? spike mutations (BA.2.86 vs XBB.1.5) from @RajlabN https://t.co/8UucaWlOaWhttps://t.co/m239bcQ2TB pic.twitter.com/f5f6at0iRO
— Eric Topol (@EricTopol) August 18, 2023

The cases' wide spread and their significant similarities suggest that growth could be rapid, Ryan Hisner—a top variant tracker who discovered the second and third identified cases, in Denmark—told Fortune.

But even if BA.2.86 does spread rapidly, it may not drive hospitalizations and deaths upward, Dr. Stuart Ray, vice chair of medicine for data integrity and analytics at Johns Hopkins’ Department of Medicine, points out.

Though the highly mutated variant is "quite divergent" from other known circulating strains, "it's unclear whether it will have a significant effect on the number of severe cases or our management/prevention strategies," he told Fortune.
BA.2.86's unusual origins

The unusual new variant might have equally unusual origins.

BA.2.86 likely developed in an immunocompromised patient with a long-term infection, multiple experts say. Such lengthy infections give the virus opportunity to repeatedly evolve and collect a large number of mutations—it's likely how Delta and Omicron came about.

But variants from immunocompromised patients rarely spread. That's why Hisner was taken aback when he spotted the variant—first identified by tracker Shay Fleishon, with Israel's Ministry of Health, and his team, in Israel—in Europe.

Because the infected Israeli patient wasn't immunocompromised, he knew that the variant had likely already made the leap from someone with a sub-par immune system to hosts with normal ones. Hisner wasn't sure when more sequences would appear, "but I figured we would see at least a few eventually," he said.

"But when they showed up in Denmark, I was really taken aback."


Can BA.2.86 out-compete leading variants?


Three main questions remain: how the variant's mutations will affect symptoms and severity, if it will take off anywhere (or everywhere), and how new XBB.1.5 COVID vaccines—slated for U.S. release in September—might hold up (in addition to our existing immunity).

The significant number of mutations in BA.2.86 portends significant changes in immune evasion, the U.K. HSA said in its Friday report. But immunity is broader than just antibodies, Bloom points out. While antibody immunity to COVID, from either infection or vaccination, lasts only three to six months on average, T-cell immunity is thought to last much longer.

"Even if a highly mutated new variant like BA.2.86 starts to spread, we will be in a far better place than we were in 2020 and 2021, since most people have some immunity" to COVID, he recently wrote.

Regardless of the vaccine's performance against it, treatments like COVID antiviral Paxlovid that don't target the virus's highly mutated spike protein should still work well, according to Rajnarayanan.

All scenarios are possible. But even if BA.2.86 were to take off in the U.S. or worldwide, "I'd be very surprised if things get as bad as they did in that first winter, or during the Delta era or that first BA.1 wave" in late 2021 and early 2022, Hisner said.


U.S. COVID deaths, hospitalizations continue upward trend

The CDC's latest U.S. COVID data on Friday showed a continued upward trend in hospitalizations, which saw a 14% rise from July 30-Aug. 5, the most recent period for which data was available. Deaths, too, were up—8% from Aug. 6-12. "Eris" EG.5 lead sequenced domestic cases, comprising an estimated 20%, followed by "Fornax" FL.1.5.1, estimated to be responsible for 13% of cases.

Globally, reported COVID cases were up 63% from mid-July through mid-August compared to the month prior, the WHO said Thursday in a situation report. It cautioned that "reported cases do not accurately represent infection rates due to the reduction in testing and reporting globally."

During that time period, only 44% of countries reported any COVID infections to the WHO—a number that could include countries that reported only one case.
 

Heliobas Disciple

TB Fanatic
(fair use applies)


Biden Plans to Request Funds to Develop New Coronavirus Vaccine
Associated Press
August 25, 2023 9:23 PM

SOUTH LAKE TAHOE, California — U.S. President Joe Biden said Friday that he is planning to request more money from Congress to develop another new coronavirus vaccine, as scientists track new waves and hospitalizations rise, though not like before.

Officials are already expecting updated COVID-19 vaccines that contain one version of the omicron strain, called XBB.1.5. It's an important change from today's combination shots, which mix the original coronavirus strain with last year's most common omicron variants. But there will always be a need for updated vaccines as the virus continues to mutate.

People should be able to start rolling up their sleeves next month for what officials hope is an annual fall COVID-19 shot. Pfizer, Moderna and smaller manufacturer Novavax all are brewing doses of the XBB update but the Food and Drug Administration will have to sign off on each, and the U.S. Centers for Disease Control and Prevention must then issue recommendations for their use.

"I signed off this morning on a proposal we have to present to the Congress, a request for additional funding for a new vaccine that is necessary, that works," Biden, who is vacationing in the Lake Tahoe area, told reporters on Friday.

He added that it's "tentatively" recommended "that everybody get it," once the shots are ready.

The White House's $40 billion funding request to Congress on August 11 did not mention COVID-19. It included funding requests for Ukraine, to replenish U.S. federal disaster funds at home after a deadly climate season of heat and storms, and funds to bolster the enforcement at the Southern border with Mexico, including money to curb the flow of deadly fentanyl. Last fall, the administration asked for $9.25 billion in funding to combat the virus, but Congress refused the request.

For the week ending July 29, COVID-19 hospital admissions were at 9,056. That's an increase of about 12% from the previous week. But it's a far cry from past peaks, like the 44,000 weekly hospital admissions in early January, the nearly 45,000 in late July 2022, or the 150,000 admissions during the omicron surge of January 2022.


~~~~~~~~
View: https://twitter.com/RNCResearch/status/1695167661645386129


RNC Research @RNCResearch
4:13 PM · Aug 25, 2023

Biden says he just "signed off" on a funding request for "a new [COVID] vaccine that is necessary that works"

VIDEO AT LINK
31 seconds
 

Heliobas Disciple

TB Fanatic
(fair use applies)


Unlocking the Secrets of COVID-19: Why Some Populations Are Hit Harder Than Others
By Institut Pasteur
August 26, 2023

Throughout the COVID-19 pandemic, the range of clinical outcomes for individuals infected with SARS-CoV-2 varied widely, from showing no symptoms to succumbing to the disease. A research team from the Institut Pasteur, the CNRS, and the Collège de France collaborated with international scientists to study the variations in immune responses to SARS-CoV-2 among populations in Central Africa, Western Europe, and East Asia.

Their findings indicate that both latent infections of cytomegalovirus and specific human genetic factors, shaped by natural selection, play roles in the differing immune responses and COVID-19 severity levels across populations. Gaining insights into the factors causing these variations could enhance patient care in future outbreaks. The study was recently published in the journal Nature.

The Institut Pasteur’s Human Evolutionary Genetics Unit, led by Lluis Quintana-Murci, investigates how human populations differ in their immune responses to infection. These differences may result from different environmental exposures or from past population history, including natural selection, shaping the patterns of genetic diversity of human groups. In this study, published in Nature, the scientists investigated the extent and causes of disparities in the responses to the SARS-CoV-2 virus, focusing on populations from different geographic and ethnic backgrounds.

During the COVID-19 pandemic, the SARS-CoV-2 virus caused a wide range of clinical manifestations, from asymptomatic infection to fatal disease. Although advanced age remains a primary risk factor, male gender, comorbidities, and various human genetic and immunological factors also contribute to disease severity. To study variations in immune responses to SARS-CoV-2 across human populations, scientists exposed immune blood cells from 222 healthy donors from Central Africa, Western Europe, and East Asia to the virus.

Single-cell RNA sequencing was used to analyze the SARS-CoV-2 responses of 22 blood cell types. These data were then combined with serological and genetic information collected from the same individuals, making it possible to assess the degree of disparity between populations in terms of their immune responses to SARS-CoV-2 and to identify contributing factors.

Scientists have identified around 900 genes that respond differently to SARS-CoV-2 between populations. Using statistical genetic analyses, they show that these disparities are mainly due to variations in blood cellular composition: the proportion of each cell type differs from one population to another.

We know that blood cell composition can be influenced by environmental factors such as exposure to cytomegalovirus (a human infection of the herpes family, which is usually harmless), and cytomegalovirus prevalence varies widely among populations: Central Africans present 99% seropositivity, in contrast to only 50% in East Asians and 32% in Europeans. The team found that an individual’s environment, specifically latent cytomegalovirus infection, will thus influence the immune cell response to SARS-CoV-2.

Furthermore, the scientists have identified around 1,200 human genes whose expression in response to SARS-CoV-2 is under the control of human genetic factors and the frequency of the alleles that regulate these genes can vary between the populations studied. Using population genetics approaches, they have identified recurrent selection events targeting genes involved in anti-viral functions.

“We know that infectious agents have had a strong impact on human survival and exerted massive selective pressures that have shaped population genetic variation. We show that past natural selection has impacted present immune responses to SARS-CoV-2, particularly in people of East Asian ancestry, in whom coronaviruses generated strong selective pressures around 25,000 years ago,” explains Maxime Rotival, a researcher in the Institut Pasteur’s Human Evolutionary Genetics Unit and co-last author of the study.

Between 1.5% and 2% of the genomes of Europeans and Asians is of Neanderthal origin. There is growing evidence of links between Neanderthal ancestry and present-day immunity to infection. By comparing the 1,200 genes identified with the Neanderthal genome, the scientists have discovered dozens of genes that both alter antiviral mechanisms and result from ancient introgression between Neanderthals and modern humans (Homo sapiens).

“Previous studies have shown the link between some of the genes identified in our study and the severity of COVID-19. Our comprehensive population-based study highlights the direct impact of genetic variants governing immune responses to SARS-CoV-2 on the severity of COVID-19. It also establishes links between past evolutionary events, such as natural selection or Neanderthal admixture, and current population disparities in immune responses and disease risk,” explains Lluis Quintana-Murci, Head of the Human Evolutionary Genetics Unit at the Institut Pasteur, Professor at the Collège de France and co-last author of the study.

“By identifying the precise cellular and molecular pathways of the genetic variants associated with COVID-19 severity, this study paves the way for precision medicine strategies that could either identify high-risk individuals or facilitate the development of new treatments,” adds Darragh Duffy, Head of the Institut Pasteur’s Translational Immunology Unit.

Reference: “Dissecting human population variation in single-cell responses to SARS-CoV-2” by Yann Aquino, Aurélie Bisiaux, Zhi Li, Mary O’Neill, Javier Mendoza-Revilla, Sarah Hélène Merkling, Gaspard Kerner, Milena Hasan, Valentina Libri, Vincent Bondet, Nikaïa Smith, Camille de Cevins, Mickaël Ménager, Francesca Luca, Roger Pique-Regi, Giovanna Barba-Spaeth, Stefano Pietropaoli, Olivier Schwartz, Geert Leroux-Roels, Cheuk-Kwong Lee, Kathy Leung, Joseph T. Wu, Malik Peiris, Roberto Bruzzone, Laurent Abel, Jean-Laurent Casanova, Sophie A. Valkenburg, Darragh Duffy, Etienne Patin, Maxime Rotival and Lluis Quintana-Murci, 9 August 2023, Nature.
DOI: 10.1038/s41586-023-06422-9
 

Zoner

Veteran Member
BREAKING: The US just found a new Covid variant in wastewater during routine test. This comes after the government began investing in new Covid equipment and a vaccine, and weeks after they informed government agencies of coming lockdowns.

How did they know they’d find new variants? Are the government officials physic? They just happened to warn of mandates in mid September and October and then find a new variant at the end of August?

Does anyone actually fall for this anymore?

H/T @gatewaypundit

 

Zoner

Veteran Member
“The study found that the chemicals released by these masks had eight times the recommended safety limit of toxic volatile organic compounds (TVOCs).

Inhaling TVOCs has been linked to health issues like headaches and nausea, while prolonged and repeated has been linked to organ damage and even cancer.”

1693204406110.png

 

Heliobas Disciple

TB Fanatic
View: https://www.youtube.com/watch?v=kzQjBcoIMYI
Pfizer fails to answer
Dr. John Campbell
Aug 27, 2023
21 min 2 sec


Question on notice not answered. How can this be acceptable? Senator Rennick, 17:30:24:12 Link the full video from the Australian Government, https://www.aph.gov.au/News_and_Event... Senate Standing Committees on Education and Employment https://www.aph.gov.au/Parliamentary_... Link the full video from the Australian Government, https://www.aph.gov.au/News_and_Event... Senator Rennick • Pfizer can't explain why its Covid Va... Does Pfizer understand what about the mechanism of the vaccine causes myocarditis and pericarditis? Vaccine safety remains of utmost priority for Pfizer. We take adverse events that are potentially associated with our COVID-19 vaccines very seriously. We closely monitor all such events and collect relevant information to share with global regulatory authorities. With hundreds of millions of doses of the original and Omicron BA.4/BA.5-adapted bivalent Pfizer-BioNTech COVID-19 vaccine administered globally, and more than 4.6 billion vaccines delivered overall, the benefit-risk profile of our vaccines is well established and remains positive for all authorised indications and age groups. To date, hundreds of millions of people around the world have received our vaccines, and serious adverse events that are unrelated to the vaccine are likely to occur at a similar rate as they would in the general population. It is important to note that every medicine – and vaccine – has side effects. However, all approved medicines and vaccines are rigorously tested in clinical trials to ensure the side effects are manageable and the benefits outweigh the risks. Pfizer is aware of rare reports of myocarditis and pericarditis, predominantly in male adolescents and young adults, after mRNA COVID-19 vaccination. According to public health and regulatory authorities around the world , the number of reports is small given the number of doses administered and patients have typically rapidly improved with conservative treatment. It’s important to note that the reported risk for myocarditis after COVID-19 infection is substantially higher when compared with reported rates for individuals without COVID-19 infection or after vaccination. In addition to following up on any clinical and spontaneously reported cases of myocarditis/pericarditis, we are conducting several large, retrospective database studies that assess vaccine safety including myocarditis/ pericarditis in each age group. These studies take time to accrue sufficient data to be informative given rarity of event. Although a number of hypotheses regarding the pathophysiological mechanisms have been put forward, the research data available are extremely scarce and the actual mechanism for the pathogenesis of this adverse event post-vaccination is far from being established. It is important to note that global regulatory authorities and medical societies continue to recommend COVID-19 vaccinations.
 

pinkelsteinsmom

Veteran Member
REad that above and weep. That MF needs to be reckoned with. Yes, please forgive me, I posted this on two threads. This must be proven to be true or a lie therefore it must be seen.
 

Heliobas Disciple

TB Fanatic
(fair use applies)


Not Over Yet: Late-Summer COVID Wave Brings Warning of More to Come
Julie Bosman - NY Times
Mon, August 28, 2023, 8:16 AM EDT

A late-summer wave of coronavirus infections has touched schools, workplaces and local government, as experts warned the public to brace for even more COVID-19 spread this fall and winter.

Hospitalizations increased 24% in a two-week period ending Aug. 12, according to the most recent data from the Centers for Disease Control and Prevention. Wastewater monitoring suggests a recent rise in COVID infections in the West and Northeast. In communities across the United States, outbreaks have occurred in recent weeks at preschools, summer camps and office buildings.

Public health officials said that the latest increase in COVID hospitalizations is still relatively small and the vast majority of the sick are experiencing mild symptoms that are comparable to a cold or the flu. And most Americans, more than three months after the Biden administration allowed the 2020 declaration calling the coronavirus a public health emergency to expire, have shown little willingness to return to the days of frequent testing, mask wearing and isolation.

But for Americans who have become accustomed to feeling the nation has moved beyond COVID, the current wave could be a rude reminder that the emerging New Normal is not a world without the virus.

“We’re in almost the best place we’ve been in the pandemic since it began,” said Michael T. Osterholm, the director of the Center for Infectious Disease Research and Policy at the University of Minnesota. “But we are caught in the very uncomfortable area of having left the fog of the pandemic war and trying to understand what the sunrise on a normal post-COVID world looks like.”

In cities across the country, the remnants of coronavirus restrictions still remain, even if they are no longer observed. Retail stores may have signs in the windows requesting that patrons wear masks, but no one inside is wearing them. Years-old stickers asking customers to stand 6 feet apart in line are faded, worn and ignored. The occasional storefronts in major cities advertise free COVID-19 testing, though the spaces inside are empty.

And the virus is still disrupting work, school and politics: A COVID outbreak tied to a City Council meeting in Nashville, Tennessee, this month left more than a dozen people infected, including council members, city employees and at least one reporter. One of the people who tested positive for COVID, Freddie O’Connell, a City Council member who is in a Sept. 14 runoff election for mayor, said it was a stark reminder that the virus had once again taken hold in the community.

“All year long, there have been many COVID spikes in my personal network, but it hasn’t felt like this, where all of a sudden we’re back to events that we used to hear about in 2020, where suddenly dozens of people in one fell swoop all get it,” O’Connell said in an interview from his home, where he had been marooned for a five-day quarantine. “I haven’t really had to think about the phrase ‘superspreader event’ in a long time.”

As students have returned to school in recent days, most administrators have signaled that they are not planning to return to stricter rules surrounding masks and testing, typically only asking parents to keep their children home when they are sick. In Chicago, where COVID-related hospitalizations are still extremely low but have crept up in recent weeks, the public school district promised to provide free rapid COVID tests to students and staff but did not intend to resume testing in schools.

Even in the face of rising COVID infections, there is a balance that should be struck in schools now, said Hedy Chang, the executive director of Attendance Works, a national group that promotes solutions to chronic absenteeism.

“We got trained to stay home for every sign of illness during the pandemic,” she said. “We actually have to shift norms again, to being judicious and thoughtful about when we keep kids home, and only keeping them home if we think it’s truly a problem.”

Dr. John M. Coleman, a pulmonary and critical care doctor at Northwestern Memorial Hospital, said he expected COVID infections to continue to increase this fall and winter, but he noted that the most recent strains of the virus were less severe than those that circulated early in the pandemic.

People who are hospitalized for COVID now tend to have preexisting conditions or suppressed immune systems that make them more susceptible to severe symptoms, he said.

“Moving forward, we have to learn to live cohesively with COVID,” Coleman said. “COVID is always going to be around.”

Particularly for people who already have health risks, he said, it is crucial to receive the new booster this fall, wash hands frequently and wear a mask if feeling unwell.

Throughout the summer, public health officials have stressed prevention and treatment in the face of an increase in cases. The Cambridge, Massachusetts, health department said in a statement this month that it saw outbreaks at nursing homes in the city and urged the public to stay up-to-date on vaccinations.

But some institutions have responded to the recent increase in COVID infections by reinstating pandemic-era rules.

In keeping with an order from the health department in Los Angeles County, the movie studio Lionsgate recently sent a memo to staff members informing them that because of a COVID outbreak among employees, they would be required to wear masks in the office again. (The health department notified the studio Friday that because it had reported no new cases, the requirement was lifted.)

Morris Brown College, a small private school in Atlanta, announced this month that it would require face masks on campus again. The school banned parties and large gatherings on campus for two weeks and said that temperature checks would be administered to students.

The Dane County, Wisconsin, jail suspended all outside visits after 49 prisoners tested positive for COVID, the Dane County Sheriff’s Office announced last week.

And in a few, isolated parts of the country, it can feel as if the pandemic never left.

Louise Tsinajinnie, a spokesperson for the Navajo Nation Parks and Recreation, said that in her office in Window Rock, Arizona, employees still wear masks at their desks.

The Navajo Nation was hit especially hard by COVID during the pandemic, she said, and cases have been on the rise again.

“Many people feel that they don’t want to get sick again,” she said. “It’s a real concern on the Navajo Nation. We do worry about our elders and we don’t want this impacting them.”
 

Heliobas Disciple

TB Fanatic
(fair use applies)


IN-DEPTH: Anticipating New COVID Mandates, Florida County Becomes Bill of Rights Sanctuary

By Patricia Tolson
8/28/2023

Rumors are stirring that another pandemic is coming.

This means a potential for more mask mandates, more lockdowns, and a new vaccine. To inoculate themselves from another round of bureaucratic and government overreach, local officials in Collier County, Florida, have declared the county to be the state's first "Bill of Rights Sanctuary."

They are joining others.

In Pennsylvania, Montour County became a Bill of Rights Sanctuary on Feb. 9, 2021.

Worcester County, Maryland, became a sanctuary for the Bill of Rights and the Constitution on May 4, 2021.

Local officials in Volusia County, Florida, tried to enact sanctuary status in 2021 but the measure failed, and Mississippi and Tennessee tried to become sanctuary states.

Before the Collier County Board of County Commissioners meeting on Aug. 22, The Epoch Times spoke with Commissioner Chris Hall, who sponsored the sanctuary measure.

According to the Collier County ordinance (pdf), the board wants to address its "growing concerns over the federal government’s increasing encroachment on the rights and privileges of its citizens."

"Of particular concern are those edicts being promulgated by the federal government in the form of executive orders, which circumvent the legislative process and arguably violate the fundamental American doctrine of separation of powers."

Mr. Hall made it clear that the ordinance is not intended to nullify constitutional federal laws but rather to protect citizens from unconstitutional mandates that bring devastating consequences to their lives and their economy.

"What we want to do here in Collier County is we want to establish an ordinance that is enforceable by the sheriff in case anything ever twists off in Washington or, God forbid, Tallahassee, of any edicts, resolutions, laws, or anything unconstitutional," he said. "We realize what the supremacy clause is and it's any laws that come down in pursuance of the Constitution."

The supremacy clause is an article in the U.S. Constitution which specifies that "laws of the United States" and "all treaties made" shall be "the supreme law of the land." The clause further provides that "judges in every state shall be bound thereby," and that federal law supersedes any conflicting state laws.

For those, he said, "We will comply, absolutely."

"But anything that is not, we don't have to and we won't, and that's going to be by law, here in Collier County," he asserted, adding that the ordinance "will protect the citizens and their constitutional, inalienable rights given to them by God."

Asked what inspired the effort to push for such a measure, Mr. Hall did not hesitate.

"COVID," he said. "Seeing the liberties of the people stripped and seeing them just letting it happen. It's why I ran for this job. I got mad at all of the injustice and I got mad at the sheeple."

Mr. Hall is aware of the rumors of more lockdowns and mandates.

"There's all kinds of talk about things that might come down from the World Health Organization," he said, recalling the "recommendations from three-letter agencies that changed our lives" the last time unelected government bureaucrats started pushing measures to restrict the rights of American citizens.


The COVID-19 Panic


On March 11, 2020, the World Health Organization (WHO) declared COVID-19 a pandemic. Millions were infected. Millions died. Panic ensued. Businesses were ordered to shut down. Schools were closed. People were advised to stay home, wear masks, limit the size of social gatherings, and stay at least six feet apart.

A study published in Emerald Open Research on July 17, 2020, concluded that the COVID-19 lockdowns and controls were a violation of fundamental human rights and, in some countries, discriminatory against minorities and vulnerable people.

A separate study confirmed that the lockdowns caused notable damage to the mental health of children and adolescents, causing a rise in the "presence of significant anxiety and depression."

In January 2022, a paper published by the Annenberg Institute at Brown University (pdf) revealed the devastating and "potentially demoralizing" effects the lockdowns, mask mandates, social distancing, and virtual schooling had on academic achievement.

While Federal Reserve economists estimate that about 600,000 businesses fail each year in the United States, a 2021 study (pdf) found that the COVID-19 lockdowns resulted in the collapse of an additional 200,000 businesses.

An analysis by ABC News in February 2020 showed that in-person attendance at church dropped by 45 percent. Just like many businesses, some churches were forced to close for good.

As lockdowns were eased and businesses and schools reopened, another chaos emerged.

A woman was assaulted with a stun gun and arrested for not wearing a mask outdoors. Parents were removed from school board meetings for not wearing masks at the meetings. Even a teen girl was arrested for not wearing a mask at school.

Fights over masks broke out on airplanes, outside of restaurants, inside restaurants, in grocery stores, and on subways. People were stabbed. Others were shot.

If you didn't or couldn't wear a mask, you couldn't go to work. You were not allowed in restaurants, movie theaters, or grocery stores. Children couldn't go to school.

People lost their jobs. Members of the military were booted from service for refusing to be vaccinated, even for religious reasons.

In December 2021, the White House announced President Joe Biden's "new actions to protect Americans against the Delta and Omicron variants," which included boosters for adults and vaccinations for children to attend school.

On May 3, 2022, the Centers for Disease Control and Prevention (CDC) issued recommendations that "everyone aged 2 and older—including passengers and workers—properly wear a well-fitting mask or respirator over the nose and mouth in indoor areas of public transportation (such as airplanes, trains, etc.) and transportation hubs (such as airports, stations, etc.)."

This "new mask guidance" was strictly enforced.

If someone tested positive or came near anyone who tested positive for COVID, they were forced to quarantine for five days and wear a mask for 10 days.


Exceeding Their Authority


It wasn't until U.S. District Judge Kathryn Kimball Mizelle struck down the CDC's mask mandate as unconstitutional on April 18, 2022, that things changed.

According to the ruling, the mandate was "unlawful" because it "exceeded the CDC's statutory authority."

While the CDC claims it derives its power to impose national lockdowns through the authority of the federal commerce clause, legal authorities say this is invalid.

As Bradley Moss, a Washington attorney specializing in national security issues, told NPR in April 2020, "absent congressional approval or every state in the union collectively agreeing to it," it's unclear "how any president would have the authority to impose a federal or national quarantine."

On Nov. 6, 2021, the U.S. Court of Appeals for the 5th Circuit put a stay on the federal government's plan to force Americans to be vaccinated, ruling that there were "grave statutory and constitutional issues" with the mandate (pdf).

It has been more than a year since President Biden declared that the pandemic was over.

But now the WHO and the CDC are monitoring yet another COVID variant.

As The Epoch Times reported on Aug. 22, mask mandates have already returned in some states. "A slight uptick in the virus" prompted two hospitals in Syracuse, New York, to bring back mandatory masking and testing.

On Aug. 23, the CDC warned that BA.2.86, the latest variant, "may be more capable of causing infection in people who have previously had COVID-19 or who have received COVID-19 vaccines."


'We Want to Be Free'

The unauthorized, unconstitutional restrictions and mandates imposed on Americans during the COVID-19 pandemic are precisely the reason Mr. Hall was so determined to get his measure passed.

"By ordinance in Collier County, Florida, we want to be free to live," Mr. Hall said. "My job as county commissioner is to protect and secure the lives of the people, and with this ordinance I think that's a good thing."

Even though "there is no evidence that this variant is causing more severe illness," the CDC said that scientists are evaluating the effectiveness of the forthcoming updated COVID-19 vaccine and that that the "CDC’s current assessment is that this updated vaccine will be effective at reducing severe disease and hospitalization."

"If licensed/authorized by the FDA and recommended by the CDC," it assured, "updated vaccines will be available as early as mid-September at your local pharmacy or doctor’s office."

Mr. Hall is also aware of how some have already reinterpreted the Constitution to circumvent the rights of the people, such as the familiar cry of "separation of church and state."

The First and 14th Amendments prohibit federal and state governments from establishing a national or state-level religion, but they do not prohibit the mention of God by the state.

Even though the phrase "separation of church and state" does not appear anywhere in the Constitution, the term is repeatedly used to justify infringements on the freedom of religion by banning prayer in public schools or prohibiting the placement of manger scenes on public property.

"That's the thing about ignorance," Mr. Hall said. "It's loud."


'The Rights to Fight Back'

As previously reported by The Epoch Times, Mr. Hall first introduced the Bill of Rights Sanctuary County measure in July 2021.

Despite support from many citizens during public comments and a stack of 231 petitions in its favor, the measure failed by a vote of 3–2.

As the board prepared to vote on Aug. 22, Mr. Hall made one more plea.

"I just want to keep it simple," he said. "This is an ordinance that will back the people. This says Collier County will honor the Constitution, will honor the Bill of Rights, will honor every federally constitutional law that comes down. If anything that comes down that is unconstitutional, or that it's obvious that it's not constitutional, the people have the rights to fight back. The people give the federal government power. The federal government does not tell the people what to do. That's the way our country was framed."

In conclusion, he said he hoped his fellow board members would join him in passing the ordinance.

Commissioner William McDaniel reaffirmed what he said two years ago.

"I believe this is a reaffirmation of the Constitution and the Bill of Rights," he said. "I believe that it's an additional protection for the citizens of Collier County and I don't think it takes away from the rights that our citizens already have, and I'm in support. Our sheriff, our congressman, our legislators are still in support of it and so am I."

Commissioner Daniel Kowal also reiterated his position from two years ago, saying the ordinance supports the Constitution and the Bill of Rights.

"It's a check and balance on us as we move forward," he said, noting how when boards in the future "are faced with another pandemic or epidemic and they have to make decisions that might violate your constitutional rights, they would have to reverse this ordinance and they would have to come out publicly and say 'I don't believe in the Bill of Rights. I don't believe in the Constitution.' And that would contradict their oath they had to take to have this seat."

"That's why I believe I have to support this," he concluded.

Commissioner Burt Saunders was "in the lonely position" of being the only one to vote against the measure.

While he called the ordinance a "well-intended exercise," he doesn't believe it's necessary. Secondly, he said "it sends the wrong message to the public," insinuating that the measure would give people the false impression that the board has the right to "determine if a rule or regulation from the federal government is constitutional."

Even though he thought the measure was "well-intended," he said, "I can't support it."


'I'm Actually Proud of It'


Board Chair Rick LoCastro prefaced his remarks by thanking the citizens for their respectful professionalism in delivering their comments to the board.

"It is the way our Founding Fathers would have wanted it," he said.

"After weighing all the input in 2021, I voted for this ordinance without hesitation," he recalled. "It failed 3–2, and I was very disappointed."

"Two years later, I remain wide open and available to all citizens and organizations to hear their views and I have for months. I don't believe this ordinance nullifies federal laws we don't like. It's a preparatory step that, as it has been said, has the citizens' backs and allows us the strength and our ability to merely question federal law if or when we feel our federal government is overreaching outside of their authority."

In summation, he said, "After careful reconsideration, I have zero reservations this time and I am proud to support it again."

"It has been said, 'Lead, follow, or get out of the way.' I'm not nervous or disappointed that we will be the first county in Florida to pass this ordinance. I'm actually proud of it," he said in closing.

By a motion of 4–1, the ordinance passed.

Keith Flaugh, a Collier Country resident who came to speak during public comment in support of the measure, was happy with the outcome.

Mr. Flaugh is the managing director and CEO of Florida Citizens Alliance (FCA). He worked closely with Mr. Hall as well as civil rights and constitutional attorney Kristina Hauser in drafting and fine-tuning the measure since it was first proposed two years ago.

"Four Collier County commissioners had the courage to reaffirm their commitment to protecting their constituents from federal government overreach," Mr. Flaugh told The Epoch Times. "We hope this inspires every county in Florida, in fact, the United States to follow suit."

In an FCA news release, Mr. Hall said he was proud to have brought back the ordinance for another vote in Collier County.

"This was a campaign promise for smaller government and common sense. This was a major move for our county to protect the liberties of our people, limit any unlawful acts by Federal or State Governments, and return the power back to the people as our framers intended.”
 

Heliobas Disciple

TB Fanatic
(fair use applies)


Pfizer Drip Feeds Data From its Pregnancy Trial
By Maryanne Demasi
August 28, 2023

In January 2021, in the absence of any human data in pregnancy, the CDC stated on its website that mRNA vaccines were “unlikely to pose a specific risk for people who are pregnant.”

Former CDC director Rochelle Walensky backed it up with a full-throated endorsement of covid-19 vaccination in pregnancy.

“There is no bad time to get vaccinated,” said Walensky.

“Get vaccinated while you’re thinking about having a baby, while you’re pregnant with your baby or after you’ve delivered your baby,” she added.

Behind the scenes however, Pfizer was scrambling to conduct a clinical trial of its vaccine in pregnant women.

By February 2022, Pfizer revealed it still did “not yet have a complete data set.” Its statement read:

“The environment changed during 2021 and by September 2021, COVID-19 vaccines were recommended by applicable recommending bodies (e.g., ACIP in the U.S.) for pregnant women in all participating/planned countries, and as a result the enrollment rate declined significantly.”

This month, Pfizer finally posted some trial results on clinicaltrials.gov.

The data do not appear in a peer-reviewed journal or a pre-print, nor has it been submitted to the FDA for evaluation.

I spoke with experts who have analysed the data with a fine-toothed comb and made some alarming observations.


Trial design

Pfizer originally planned to recruit 4,000 healthy women aged 18 or older who were 24 to 34 weeks pregnant. Half would be randomised to the vaccine and the other half to a saline placebo.

The efficacy and safety of the vaccine would be determined by assessing covid-19 cases, antibody responses, and adverse events.

Peculiarly, Pfizer planned to vaccinate all the mothers in the placebo group, one month after giving birth to their babies.

Retsef Levi, a professor at the Massachusetts Institute of Technology Sloan School of Management said that vaccinating mothers in the placebo group during the assessment period would introduce a new variable into the experiment and “corrupt” the data.

“We now know that mRNA from the vaccine is detected in the breast milk, so those babies born from mothers who were all vaccinated after giving birth, are also potentially exposed to mRNA through breastfeeding,” explained Levi.

“This corrupts the comparison of the two groups of babies because you don’t have a true control group anymore,” he added.


Sample size too small

Less than 10 percent of the originally planned 4,000 study participants ended up in the trial.

“Only 348 women were recruited – 174 in each arm – meaning that the trial was never going to have the statistical power, particularly when analysing potential harms,” said Levi.

Notably, study protocols indicate that Pfizer was given the green light as early as May 2021 by drug regulators to scale back the trial and reduce the sample size.

https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc81d9cba-d4a3-479b-aa7b-072e32c9f95f_752x207.png


“To me, the wording in the protocol suggests that the FDA or another regulator basically gave Pfizer permission to do less,” remarked Levi.

“It’s not surprising though. The vaccine had already been recommended for pregnant women and many have taken it, so there is no upside to completing a trial that may detect signals of potential harms. It can only create problems for them, right?” he added.

Given that pregnant women were being vaccinated with a product that had not undergone rigorous safety testing in pregnancy, the FDA was asked if and why it allowed Pfizer to scale back the trial.

The FDA replied, “As a general matter, FDA does not comment on interactions it may or may not be having with sponsors about their clinical trials.”

Angela Spelsberg, an epidemiologist and medical director at the Comprehensive Cancer Center Aachen in Germany agreed that the integrity of the study had been compromised.

“There are just not enough babies in this trial to detect rare or very rare adverse events. We learned from studies in animals that lipid nanoparticles in the vaccine can deposit in many organs including the ovaries, so we must be extremely cautious about the potential negative impacts of the vaccine on reproductive health,” said Spelsberg.

“The scientific community urgently needs access to the pregnancy study data on the patient level for transparency and independent scrutiny of vaccine safety and efficacy because regulatory oversight is failing,” she added.


Exclusion criteria

The small sample size may have been the result of the strict selection process.

Pfizer recruited participants with an impeccable pregnancy history, and most were in their third trimester (27-34 weeks gestation), a stage when the baby’s major development has already occurred.

“It appears that they cherry picked the mothers to get the best results,” said Levi. “We have no idea what impact this vaccine has on the early stages of development of an embryo or foetus, because all the women had advanced pregnancies when they were recruited.”

Spelsberg agreed.

“The first trimester is particularly vulnerable to adverse reproductive health outcomes,” she said.

“Based on only weak observational evidence, regulators have reassured the public that the vaccines are safe throughout pregnancy. However, we don’t have reliable evidence on the vaccine’s impact on miscarriages, malformation, foetal deaths, and maternal health risks because they excluded pregnant women from pivotal trials,” added Spelsberg.


Missing data

Levi also noticed that “only partial data” were published.

“It doesn’t include any important metrics such as covid infections or antibody levels and its says we must wait until July 2024 for those results. It’s disturbing to say the least,” said Levi.

Also missing from the dataset was a full account of birth outcomes. Of the 348 women in the trial, Pfizer only reported on the birth of 335 live babies.

Of the 13 pregnancies unaccounted for, Pfizer reported one foetal death (stillbirth) in the vaccine group and the outcome of the other 12 pregnancies remains unknown.

“This is unacceptable,” said Levi. “Failing to report the outcome of 12 pregnancies could mask a potentially concerning signal of the vaccine in pregnancy. What happened to the babies, did they all die? Were their mothers vaccinated or unvaccinated?”


Trial dropouts

Finally, there were quite a few babies that were lost to follow-up in the trial.

“Twenty-nine babies in the placebo arm didn’t get to the end of the 6-month surveillance period, versus 15 babies in the vaccine arm. That’s almost double. Again, this is concerning and requires a detailed and transparent explanation,” said Levi.

Overall, both Levi and Spelsberg say the delays and failure to disclose vital data are unacceptable.

“Pfizer took a year to publish the data. When they finally did, it is incomplete. And we are expected to wait until July 2024 for the next batch of results, while authorities continue to recommend the vaccine in pregnant women,” said Levi.

“We still don’t have solid scientific evidence whether this vaccine is safe for pregnant women and their babies,” said Spelsberg. “It’s a tragedy and a scandal that vaccine use has been recommended, even mandated to women before, during and after pregnancy.”

Questions were put to Pfizer, but the company did not respond by the deadline.

Moderna is also conducting a clinical trial of its mRNA vaccine in pregnancy, but no data are available.


Reprinted from the author’s Substack
 

Heliobas Disciple

TB Fanatic
(fair use applies)


Scientists Sound the Alarm: COVID-19 Virus Is Rapidly Evolving in White-Tailed Deer
By Ohio State University
August 28, 2023

Study finds deer are virus reservoirs, promoting ongoing mutation.

New research has found that white-tailed deer across Ohio have been infected with the virus that causes COVID-19. Alarmingly, the results also show that viral variants evolve about three times faster in deer than in humans.

Scientists collected 1,522 nasal swabs from free-ranging deer in 83 of the state’s 88 counties between November 2021 and March 2022. More than 10% of the samples were positive for the SARS-CoV-2 virus, and at least one positive case was found in 59% of the counties in which testing took place.


Genomic Analysis and Findings


Genomic analysis showed that at least 30 infections in deer had been introduced by humans – a figure that surprised the research team.

“We generally talk about interspecies transmission as a rare event, but this wasn’t a huge sampling, and we’re able to document 30 spillovers. It seems to be moving between people and animals quite easily,” said Andrew Bowman, associate professor of veterinary preventive medicine at The Ohio State University and co-senior author of the study.

“And the evidence is growing that humans can get it from deer – which isn’t radically surprising. It’s probably not a one-way pipeline.”

The combined findings suggest that the white-tailed deer species is a reservoir for SARS-CoV-2 that enables continuing mutation, and that the virus’s circulation in deer could lead to its spread to other wildlife and livestock.

The study is published today (August 28, 2023) in the journal Nature Communications.


Previous Observations and Expansions


Bowman and colleagues previously reported detection of SARS-CoV-2 infections in white-tailed deer in nine Ohio locations in December 2021, and are continuing to monitor deer for infection by more recent variants.

“We expanded across Ohio to see if this was a localized problem – and we find it in lots of places, so it’s not just a localized event,” Bowman said. “Some of the thought back then was that maybe it’s just in urban deer because they’re in closer contact with people. But in rural parts of the state, we’re finding plenty of positive deer.”

Beyond the detection of active infections, researchers also found through blood samples containing antibodies – indicating previous exposure to the virus – that an estimated 23.5% of deer in Ohio had been infected at one time or another.


Variant Analysis

The 80 whole-genome sequences obtained from the collected samples represented groups of various viral variants: the highly contagious delta variant, the predominant human strain in the United States in the early fall of 2021 that accounted for almost 90% of the sequences, and alpha, the first named variant of concern that had circulated in humans in the spring of 2021.

The analysis revealed that the genetic composition of delta variants in deer matched dominant lineages found in humans at the time, pointing to the spillover events, and that deer-to-deer transmission followed in clusters, some spanning multiple counties.

“There’s probably a timing component to what we found – we were near the end of a delta peak in humans, and then we see a lot of delta in deer,” Bowman said. “But we were well past the last alpha detection in humans. So the idea that deer are holding onto lineages that have since gone extinct in humans is something we were worried about.”

The study did suggest that COVID-19 vaccination is likely to help protect people against severe disease in the event of a spillover back to humans. An analysis of the effects of deer variants on Siberian hamsters, an animal model for SARS-CoV-2 studies, showed that vaccinated hamsters did not get as sick from infection as unvaccinated animals.


Rapid Evolution in Deer

Disturbingly, the variants circulating in deer are expected to continue to change. An investigation of the mutations found in the samples provided evidence of more rapid evolution of both alpha and delta variants in deer compared to humans.

“Not only are deer getting infected with and maintaining SARS-CoV-2, but the rate of change is accelerated in deer – potentially away from what has infected humans,” Bowman said.

How the virus is transmitted from humans to white-tailed deer remains a mystery. And so far, even with about 30 million free-ranging deer in the U.S., no substantial outbreaks of deer-origin strains have occurred in humans.


Potential Implications


Circulation among animals, however, remains highly likely. Bowman noted that about 70% of free-ranging deer in Ohio have not been infected or exposed to the virus, “so that’s a large body of naive animals that the virus could spread through rather uninhibited.”

“Having that animal host in play creates things we need to watch out for,” he said. “If this trajectory continues for years and we have a virus that becomes deer-adapted, then does that become the pathway into other animal hosts, wildlife or domestic? We just don’t know.”

Reference: “Accelerated evolution of SARS-CoV-2 in free-ranging white-tailed deer” 28 August 2023, Nature Communications.
DOI: 10.1038/s41467-023-40706-y

Martha Nelson of the National Library of Medicine was co-corresponding author of the study. Ohio State co-authors Dillon McBride, Steven Overend, Devra Huey, Amanda Williams, Seth Faith and Jacqueline Nolting worked on the study with co-authors from St. Jude Children’s Research Hospital; the University of California, Los Angeles; the National Research Centre in Giza, Egypt; PathAI Diagnostics; the Ohio Department of Natural Resources; the U.S. Department of Agriculture; Columbus and Franklin County Metroparks; and the Rega Institute for Medical Research in Belgium.

This work was supported by the National Institute of Allergy and Infectious Diseases and Ohio State’s Infectious Diseases Institute.
 

Heliobas Disciple

TB Fanatic
(fair use applies)


American study estimates 1.87 million excess deaths occurred in China two months after its zero COVID policy ended
by Bob Yirka , Medical Xpress
August 25, 2023


american-study-shows-1.jpg

Observed Mortality and Baidu Index (BI) in Beijing and Heilongjiang Province. A and B, left panels: Observed monthly mortality rate in 3 universities of China, and BI (monthly mean) in Beijing and Heilongjiang province, January 2016 to January 2023. The dotted vertical line represents the removal of the zero COVID policy in December 2022. The figure displays the BI trends, represented by light blue lines. Dark blue lines represent morality rates in Tsinghua University (THU) (A, left panel) and Harbin Institute of Technology (HIT) (B, left panel), and the light gray line represents mortality rates in Peking University (PKU) (A, left panel). A and B, right panels: Association between weekly death counts and BI (weekly mean), November 2022 to January 2023. Weekly deaths from PKU and HIT were used. Weekly death counts from THU were not obtainable. The orange, brown, and gray squares represent weeks in November 2022, December 2022, and January 2023, respectively. Credit: JAMA Network Open (2023). DOI: 10.1001/jamanetworkopen.2023.30877


A pair of public health researchers at the Fred Hutchinson Cancer Research Center's Public Health Sciences Division, in Seattle, Washington, working with two independent colleagues, has found that in the two months after China halted its zero COVID policy at the end of 2022, 1.87 million excess deaths occurred in that country.

In their study, reported in JAMA Network Open, the group used obituary data from three Chinese universities along with other data obtained using the Baidu search engine regarding deaths in China likely due to COVID-19.

During the initial phase of the COVID-19 pandemic, deaths from the disease were remarkably lower in China than in other countries. This was due, it is believed, to officials in China enacting a program called the zero COVID policy that placed tight restrictions: People were ordered to quarantine, and authorities enacted a program of regular testing, closed many workplaces and schools and instituted mandatory mask policies.

Such restrictions took a tremendous toll on the Chinese economy, and the government eased restrictions, finally doing away with the zero COVID policy in December 2022. Two months later, the Chinese government reported that approximately 60,000 people had died from the disease up to that point. In this new effort, the research team took another route to assess the Chinese death tally following the lifting of the zero COVID policy.

As has been done in the U.S. and other countries by other teams, the researchers ignored figures cited by official government agencies regarding the number of people that died of COVID-19 over the course of the pandemic. Instead, they analyzed excess deaths derived from sources listing the number of people who died over a given period of time and comparing those numbers against the same period of time in other years. The difference, they suggest, is likely due to COVID-19 deaths categorized as something else.

In this new effort, the research team obtained data published by three universities in China and also used data found using the Baidu search engine for deaths of people over 30 by any cause in the areas where the three universities were located. They used math techniques to estimate deaths across the whole country for the two months following cessation of the zero COVID policy—it came to approximately 1.87 million excess deaths.

More information: Hong Xiao et al, Excess All-Cause Mortality in China After Ending the Zero COVID Policy, JAMA Network Open (2023). DOI: 10.1001/jamanetworkopen.2023.30877
Journal information: JAMA Network Open
 

Heliobas Disciple

TB Fanatic
(fair use applies)


New grasp of key COVID-19 protein may lead to a live-attenuated vaccine effective against more variants for longer
by Brendan M. Lynch, University of Kansas
August 28, 2023


new-grasp-of-key-covid-2.jpg

SARS-CoV-2 nonstructural protein three domains and location of Mac1 in SARS-CoV-2 genome. (A) Cartoon diagram illustrating the different domains of SARS-CoV-2 nsp3. (B) Schematic of the SARS-CoV-2 genome with location of Mac1, indicating the area of the Mac1 deletion and the point mutations that were engineered. Credit: Proceedings of the National Academy of Sciences (2023). DOI: 10.1073/pnas.2302083120



Research from the University of Kansas published in Proceedings of the National Academy of Sciences could hasten development of a new class of vaccines aimed at SARS-CoV-2, the virus that causes COVID-19.

Anthony Fehr, associate professor of molecular biosciences, led research into a protein dubbed "Mac1," which has intrigued molecular bioscientists as an antiviral target because it's known to help confer virulence, or the power to cause disease. Results have spurred several groups, including the Fehr lab, to begin developing novel inhibitors of Mac1.

"We've built up a body of literature showing this gene is critical for the virus to cause disease," Fehr said. "To better understand this protein, we use what's called reverse genetics, where we can delete or mutate this gene so it no longer functions in the context of the actual virus. While we've done this in a lot of different coronaviruses, we hadn't actually explored this in SARS-CoV-2 until just recently. This paper really describes our efforts to get rid of this protein Mac1 in SARS-CoV-2 and really see what's happening."

Studying how SARS-CoV-2 behaved in mouse models, Fehr's collaborator at Oklahoma State, Rudra Channappanavar and his group, found that without Mac1, the virus barely had an impact on the health of mice.

"If you look at the mouse data, we find that every mouse survived and showed no real signs of disease when they were infected with the virus without this gene, whereas when we give mice the normal virus—we would call it the 'wild-type' virus—every mouse dies," Fehr said. "So, there's a huge discrepancy in the ability of those viruses to cause disease. These results further demonstrate that Mac1 is a strong target for the development of novel antiviral therapies."

What's more, Fehr and his co-authors found the virus, without the Mac1 protein, induced a robust initial immune response in mice, the kind of biological response researchers look for in a vaccine target.

"That first response you have to a virus, called an innate immune response, is dramatically increased in this infection," said the KU researcher. "When we infect the mice, this further improves the adaptive immune response, which is that T- and B-cell response we get that produces antibodies and antiviral T-cells later on—that can really protect us from future disease."

Fehr and Channappanavar have already shown that prior infection with the attenuated virus can be protective for mice from a future infection.

"Right now, we're really looking at further developing this virus into a live attenuated vaccine for SARS-CoV-2, and we're working on different strategies with minor modifications to this virus to make it even better," he said. "We think this is a great start to developing a vaccine that we think would have longer lasting immunity."

Fehr said such a vaccine could be administered intranasally, targeting the lung, giving it advantages over today's recommended vaccine regimen based on mRNA technology.

"One of the major problems with the current vaccines is that we give them in your arm—when you give a vaccine in your arm or your muscle, you don't really get great immune responses in your lungs," he said. "We think that live-attenuated vaccines given intranasally can improve that response."

Additionally, live-attenuated COVID-19 vaccines could last longer than current vaccines requiring boosters.

"I don't want to diss mRNA vaccines—they're great," Fehr said. "But they're not particularly long-lasting. We're finding their immunity wanes over the course of time. Live-attenuated viruses have been around for decades, and many of them are very effective and last very long. We can get a lot of live-attenuated vaccines as children, and we never have to take them again because they last our lifetime."

According to Fehr, a live-attenuated vaccine would target parts of the virus more likely to remain the same from variant to variant.

"All the current vaccines out there are really focused on a small portion of that spike glycoprotein that's on the outside surface of the virus," Fehr said. "There are a lot of parts of that that don't change, and they're sensitive to the current vaccines. But if there are changes in the spike protein, will those vaccines keep working? Mostly, they do. But some of them do lose efficacy."

Fehr said a whole-virus vaccine, like the one his lab is investigating, could target regions of the genome that don't change from variant to variant.

"It could reduce what I call 'variant chasing' that we have with a lot of our different vaccines now," he said. "Hopefully this approach targeting the Mac1 could be beneficial in preventing disease from future variants."

Fehr's KU collaborators were lead author Yousef M. Alhammad, a former postdoctoral researcher, along with postdoctoral researcher Srivatsan Parthasarathy, doctoral students Joseph O'Connor, Catherine Kerr and Jessica Pfannenstiel; and Robert Unckless, associate professor of molecular biosciences, Edward & Thelma Wohlgemuth Faculty Scholar and director of the KU Center for Genomics. They were joined by co-authors Roshan Ghimire, Debarati Chanda, Caden Miller, Sunil More and Rudragouda Channappanavar from Oklahoma State University and Sonia Zuniga and Luis Enjuanes of the National Centre for Biotechnology, Campus Universidad Autónoma de Madrid in Spain.

"I'm really proud of this group. We all came together, worked really hard and produced some really great science," Fehr said.

More information: Yousef M. Alhammad et al, SARS-CoV-2 Mac1 is required for IFN antagonism and efficient virus replication in cell culture and in mice, Proceedings of the National Academy of Sciences (2023). DOI: 10.1073/pnas.2302083120
Journal information: Proceedings of the National Academy of Sciences

Provided by University of Kansas
 
Top